STAGE IIIB BREAST CANCER

This early-phase trial tests a DNA vaccine called STEMVAC in 42 people with advanced HER2-negative breast cancer. The vaccine is designed to help the immune system recognize and attack cancer stem cells, which are often resistant to standard treatments. The main goals are to chec…

This study tested whether adding trastuzumab to standard chemotherapy before surgery helps shrink breast tumors more effectively. About 92 women with early-stage breast cancer (some HER2-positive, some HER2-negative) took part. The goal was to see if the combination reduces the a…

This study tests whether combining the immunotherapy drug avelumab with other medications can help people with advanced triple-negative breast cancer. About 145 adults with stage IV or inoperable breast cancer will receive one of several drug combinations. The goal is to see if t…

This study tested a chemotherapy combination (carboplatin and nab-paclitaxel) given before surgery to people with a fast-growing type of breast cancer called triple negative. The goal was to shrink tumors enough so that no cancer remains at the time of surgery. The study included…

This study tests whether platinum-based chemotherapy (cisplatin or carboplatin) works better than capecitabine in people with a certain type of triple-negative breast cancer that still remains after initial chemotherapy and surgery. About 415 participants with stage II or III bre…

This phase 3 study tests whether a combination of two hormone-blocking drugs (fulvestrant and anastrozole) works better than anastrozole alone to shrink estrogen receptor-positive breast cancer before surgery. About 1,473 postmenopausal women with stage II or III breast cancer wi…

This study tests whether a special PET scan using copper Cu64-DOTA-trastuzumab can predict how well HER2-positive breast cancer responds to targeted drugs (trastuzumab and pertuzumab) before surgery. About 18 women with locally advanced breast cancer will receive the scan and the…